SESSION TITLE: Pharmacotherapuetics
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: We studied tiotropium Respimat® (tioR) add-on to ICS plus other controller medications in 6-17 year-olds with severe symptomatic asthma.
METHODS: Pooled analysis was performed of two 12-week studies comparing tioR 2.5 µg (2 puffs, 1.25 µg) and 5 µg (2 puffs, 2.5 µg) with placebo Respimat® (VivaTinA-asthma, NCT01634152, 6-11 year-olds, and PensieTinA-asthma, NCT01277523, 12-17 year-olds). The primary endpoint was peak FEV1(0-3h) change from baseline at 12 weeks; secondary endpoints included trough FEV1, ACQ, rescue medication use and exacerbations.